Active Cancer Cells, Biochemistry & Physiology

Redirecting TGF-β signalling, inspired by adaptive evolution of parasite mimics.

In plain English

AI plain-English summary

A parasitic worm’s evolutionary toolkit is teaching researchers how to hijack a single human signalling pathway in multiple, cell-specific ways—without the toxic side effects that have plagued drug development for decades. The Transforming Growth Factor-β (TGF-β) pathway is essential for tissue maintenance and immune regulation, but when it goes wrong it drives cancer and fibrosis. Drugs that block the pathway broadly cause severe side effects because TGF-β acts on nearly every cell type. The parasite *Heligmosomoides polygyrus* secretes modular proteins—TGF-β mimics (TGMs)—that bind different co-receptors on different cells: TGM1 and TGM4 target CD44 on blood cells, TGM6 targets LRP1 on fibroblasts, and TGM7 targets gp130 on liver cells. Some TGMs activate signalling, others block it, depending on the cell type. This is a level of precision the human cytokine itself cannot achieve. If the researchers can reverse-engineer these modular structures, they could design drugs that either boost or suppress TGF-β signalling in specific tissues—turning off fibrosis in the lungs without disrupting immune function elsewhere, or promoting regulatory immune cells in autoimmune disease without affecting wound healing. This is fundamental science, inspired by an evolutionary arms race, with direct potential to reshape how we treat a broad class of chronic diseases.

View original technical description
The Transforming Growth Factor-β (TGF-β) pathway, which arose in early non- bilaterian metazoans, is essential for development and maintenance of tissues and for promoting pro-tolergenic signalling and immune homeostasis. However, dysregulation of this pathway underlies a wide range of human diseases, including cancer and tissue fibrosis. Owing to its ubiquitous role and its diverse modes of action, targeting TGF-β signaling often leads to adverse off- target effects. Here, we propose an evolutionary approach to address this crucial issue by harnessing, at the molecular level, the natural defence mechanisms of the helminth Heligmosomoides polygyrus. This parasite secretes modular TGF-β mimics (TGMs) that bind mammalian TGF-β receptors together with diverse cell surface co-receptors: TGM1 and TGM4 bind to CD44 on haematopoietic cells, TGM6 to LRP1 on fibroblasts, and TGM7 to gp130 on hepatocytes. TGM1 and TGM4 promote immune regulatory cells, while TGM6, lacking the module binding TGF-βRI, can block signalling, but only in cells expressing LRP-1. Different TGMs can thereby agonise or antagonise TGF-βR signalling in a context-dependent manner that the host cytokine cannot achieve. This remarkable evolutionary adaptation by the helminth provides a template to investigate and design new structures with novel functions with high potential for modulating TGF-β signalling in human diseases.

View the original record at the funder ↗

Researchers

Andrew Hinck (EPMC Awardee)Henry McSorley (EPMC Awardee)Peter ten Dijke (EPMC Awardee)Richard Maizels (EPMC Awardee)

Related Research

Grants with similar aims, by meaning.

Molecular and Cellular Interactions in Helminth Infections
TGF-beta activation by gut dendritic cells: identifying a critical pathway in regulation of chronic parasitic infection
Understanding TGF beta activation in health and disease
Small molecule analogues (SMAs) of an immunomodulatory helminth product provide a novel approach to dissecting macrophage signal transduction pathways
Determining a novel pathway that controls TGF-beta activation in the immune system.

Original classification

Discovery Award

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.